Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | KK2269 |
| Synonyms | |
| Therapy Description |
KK2269 is a bispecific antibody that targets CD40 expressed on antigen presenting cells (APCs) and EPCAM expressed on tumor cells, resulting in EPCAM-dependent activation of CD40 signaling, which potentially enhances antitumor immune response and delays tumor growth (Cancer Res (2024) 84 (6_Supplement): 5310; Cancer Res (2024) 84 (6_Supplement): 5311). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| KK2269 | KK-2269|KK 2269 | CD40 Antibody 16 | KK2269 is a bispecific antibody that targets CD40 expressed on antigen presenting cells (APCs) and EPCAM expressed on tumor cells, resulting in EPCAM-dependent activation of CD40 signaling, which potentially enhances antitumor immune response and delays tumor growth (Cancer Res (2024) 84 (6_Supplement): 5310; Cancer Res (2024) 84 (6_Supplement): 5311). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06266299 | Phase I | Docetaxel + KK2269 KK2269 | A Study of KK2269 in Adult Participants With Solid Tumors | Recruiting | USA | 1 |